Alzheimer's disease - donepezil, rivastigmine, galantamine and memantine (review): final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it.
Please note that the appeal period for this appraisal will close at 5pm on 1 July 2009.
This page was last updated: 15 February 2011